Trending...
- San Francisco Bay Area Songwriting Duo Razteria and Dave Shul Release Retro Rock Pop Album Prowess Blossoming
- Who is Stan Fitzgerald Georgia Veterans for America First state chapter Political Director
- 4th Annual Pompano Fall Festival: Shirley Murdock, Adina Howard, Jeezy, and Plies Headline Broward County's Top Music Festival
Supermajority of RENB Shareholders Support Appointment of New CEO and the Replacement of Entire Board of Directors with Full Five-Member Slate.
LOS ANGELES - DelhiScan -- Realignment to Optimize & Commercialize RenovaroCube, Disruptive AI Platform for Multi-omics Diagnostics for Cancer Early Detection and Patient Monitoring from Liquid Biopsies.
New Board Encompass Seasoned Veterans from Capital Markets, Governance, AI, Biotechnology, Cancer Detection and Treatment.
Restructuring to Accelerate Growth, Commercialization, Access to Strategic Capital and Create Long-Term Value for Shareholders.
Renovaro, Inc. (Stock Symbol: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. RENB includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.
Strategic Restructuring and Leadership Transition
On October 16th RENB announced a strategic restructuring and leadership transition of senior management and the Board of Directors to realign resources focused on the Company's AI Platform, RenovaroCube for multi-cancer early detection and patient monitoring. The RENB Board, with the support of a supermajority of shareholders, appointed David Weinstein as director and new CEO and four new directors – Maurice van Tilburg, Chairman, Douglas Calder, James A. McNulty CPA, and Mark A. Collins PhD.
More on Delhi Scan
RENB new leadership led by David Weinstein, CEO, renowned senior Wall Street executive with 39 years in banking & analyst roles, recognized for developing dynamic growth strategies for a broad range of private and public companies with a focus on maximizing the value of innovative life science platforms.
RENB CEO David Weinstein commented, "The new five-member board is led by the new Chairman, Maurice van Tilburg, former CEO of Euronext Amsterdam and Director at the Netherlands National Growth Fund". Maurice brings a wealth of experience in Corporate Governance, operations, and product development critical to executing on RenoVision 2.0. Moreover, he is based in Amsterdam to assist our AI driven early cancer detection program at RenovaroCube."
Mr. Weinstein continued, "The rest of our experienced Board of Directors includes: James A. McNulty: after a 26 year-career as founder of three CPA firms, Mr. McNulty has served as CFO of several publicly traded Biopharmaceutical companies including 15 years at BioDelivery Sciences International.Douglas W. Calder: For the last 24 years Mr. Calder has served in a number of senior life science executive roles with a focus on cancer immunotherapy and is currently co-founder and president of Vycellix Inc., a company developing cell-based therapeutics, headquartered in Tampa, Florida at the Moffitt Cancer Center with scientific operations in Stockholm, Sweden on the Karolinska Institute campus.Mark A Collins, PhD: co-founded three companies in drug discovery, artificial intelligence, and the software space. Mark has strong knowledge of commercializing products and platforms in oncology diagnostics."
RENB Revitalized Commitment to "Ambitious Innovation" Includes:
1) Strategic Asset Review & Pipeline Prioritization.
More on Delhi Scan
2) Commitment to Develop RENB RenovaroCube as Best-in-Class Platform, while Securing World-Class Enabling Partnerships (Corporate & Academic).
3) Optimizing, Enhancing & Accelerating Cell Therapy Pipeline Clinical Advancement.
4) Financial Initiatives to Ensure the RENB Balance Sheet Strength in Tandem with Fiscal Responsibility including Strict Budget Discipline.
5) Synchronizing All Aspects of RRNB Business Units to Yield Maximum Benefits to Patients and Shareholders.
Independent Expert Assessment Validates RENB RenovaroCube's Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
Assessment by specialist AI team from "PersonalAIze" Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
On September 19th RENB announced thart PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of the RENB RenovaroCube's advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which the RENB RenovaroCube is based.
Advancing AI models by leveraging the latest state-of-the-art techniques.
Selecting optimal patient groups for data collection and evaluating models and final products in clinical settings.
Company Websites: www.renovarobio.com and https://www.compasslivemedia.com/renb/
Media Contact
Company Name: Renovaro Inc.
Contact Person: David Weinstein, CEO
Email: ir@renovarobio.com
Phone: 732-780-5036
Home Country: United States
Disclaimer and Disclosure: www.aibrandnetwork.com
New Board Encompass Seasoned Veterans from Capital Markets, Governance, AI, Biotechnology, Cancer Detection and Treatment.
Restructuring to Accelerate Growth, Commercialization, Access to Strategic Capital and Create Long-Term Value for Shareholders.
Renovaro, Inc. (Stock Symbol: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. RENB includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.
Strategic Restructuring and Leadership Transition
On October 16th RENB announced a strategic restructuring and leadership transition of senior management and the Board of Directors to realign resources focused on the Company's AI Platform, RenovaroCube for multi-cancer early detection and patient monitoring. The RENB Board, with the support of a supermajority of shareholders, appointed David Weinstein as director and new CEO and four new directors – Maurice van Tilburg, Chairman, Douglas Calder, James A. McNulty CPA, and Mark A. Collins PhD.
More on Delhi Scan
- Loyal American Airlines Passenger and Son of 33-Year Employee Files Legal Action Against Airline for Racial Bias, Unlawful Ban, and Injustice
- OneSolution® Dental Implant Centers Offers Advanced Zygomatic Dental Implant Solutions
- Pittsburgh Professional Women invites all Women and Allies to MONEY CLUB
- Speranza Dental Implant Center's New Website Launch!
- Education Through Music-Los Angeles to Host 19th Year Benefit Gala on Friday December 6th at Skirball Cultural Center
RENB new leadership led by David Weinstein, CEO, renowned senior Wall Street executive with 39 years in banking & analyst roles, recognized for developing dynamic growth strategies for a broad range of private and public companies with a focus on maximizing the value of innovative life science platforms.
RENB CEO David Weinstein commented, "The new five-member board is led by the new Chairman, Maurice van Tilburg, former CEO of Euronext Amsterdam and Director at the Netherlands National Growth Fund". Maurice brings a wealth of experience in Corporate Governance, operations, and product development critical to executing on RenoVision 2.0. Moreover, he is based in Amsterdam to assist our AI driven early cancer detection program at RenovaroCube."
Mr. Weinstein continued, "The rest of our experienced Board of Directors includes: James A. McNulty: after a 26 year-career as founder of three CPA firms, Mr. McNulty has served as CFO of several publicly traded Biopharmaceutical companies including 15 years at BioDelivery Sciences International.Douglas W. Calder: For the last 24 years Mr. Calder has served in a number of senior life science executive roles with a focus on cancer immunotherapy and is currently co-founder and president of Vycellix Inc., a company developing cell-based therapeutics, headquartered in Tampa, Florida at the Moffitt Cancer Center with scientific operations in Stockholm, Sweden on the Karolinska Institute campus.Mark A Collins, PhD: co-founded three companies in drug discovery, artificial intelligence, and the software space. Mark has strong knowledge of commercializing products and platforms in oncology diagnostics."
RENB Revitalized Commitment to "Ambitious Innovation" Includes:
1) Strategic Asset Review & Pipeline Prioritization.
More on Delhi Scan
- Celebrating A Decade Of Young Storytellers: The 10th Annual Flint Youth Film Festival Opens For Entries
- Tween Magazine Launches to Empower and Inspire Preteen Girls
- IOTAP (Work 365) Earns SOC 2 Type II Compliance, Reinforcing Data Security Leadership
- Lake Norman Philharmonic - Annual Holiday Concert
- "Federal Complaint Filed: David Medeiros Uncovers Medicaid Mismanagement, ADA Violations, and Systemic Failures in Connecticut"
2) Commitment to Develop RENB RenovaroCube as Best-in-Class Platform, while Securing World-Class Enabling Partnerships (Corporate & Academic).
3) Optimizing, Enhancing & Accelerating Cell Therapy Pipeline Clinical Advancement.
4) Financial Initiatives to Ensure the RENB Balance Sheet Strength in Tandem with Fiscal Responsibility including Strict Budget Discipline.
5) Synchronizing All Aspects of RRNB Business Units to Yield Maximum Benefits to Patients and Shareholders.
Independent Expert Assessment Validates RENB RenovaroCube's Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
Assessment by specialist AI team from "PersonalAIze" Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform
On September 19th RENB announced thart PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of the RENB RenovaroCube's advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which the RENB RenovaroCube is based.
Advancing AI models by leveraging the latest state-of-the-art techniques.
Selecting optimal patient groups for data collection and evaluating models and final products in clinical settings.
Company Websites: www.renovarobio.com and https://www.compasslivemedia.com/renb/
Media Contact
Company Name: Renovaro Inc.
Contact Person: David Weinstein, CEO
Email: ir@renovarobio.com
Phone: 732-780-5036
Home Country: United States
Disclaimer and Disclosure: www.aibrandnetwork.com
Source: Corporate Ads
0 Comments
Latest on Delhi Scan
- Kids and Culture, LLC Recognized as a Top 100 MBE®
- Compliant Workspace Expands Microsoft 365 Data Backup Service to Empower Small Businesses on the Cloud
- Expansion to 60 Direct-Operate Stores for Profitable Coffee and Bakery Brand Operating in USA & China: Chanson: Stock Symbol: CHSN)
- Integris Composites Produces Armor for Boeing MH-139A Grey Wolf Rotorcraft
- $280B Invested, Mental Health Worsens—CCHR Demands Audit and Accountability
- Transgender Day of Remembrance 2024: A National Collaborative Honoring, Remembering, and Celebrating
- Scriptor Software Unveils Free AI-Powered Software for Radiology Impressions
- ReadyCommunities Partnership/CCROA Announces 2024 National Service Awardee: Smith Point Sea Rescue for 50 Years All-Volunteer Service
- Yunishigawa Onsen, Renowned for its Therapeutic Hot Spring Water, Hosts Annual Kamakura Festival January 31 – March 2, 2025
- purelyIV Launches Mobile App for Seamless Wellness Management
- Arthur Murray Dance Studio of Torino
- Personal Ties to Judges and Officials Raise Serious Concerns in Colorado Custody Case
- 10 Key Points to learn about local Custom Home Builders Before Considering Houses in Huntsville, AL
- National Minority Health Association welcomes leading patient advocate, Shamekka Marty as Ambassador for Health is for EveryBODY™
- Inframark Executes Multi-Year Wastewater Operations and Maintenance Contract with Fayetteville, Arkansas
- Montreal-based Blockchain Innovator, IP-House Metafy Announces Partnership With Driver Studios For Metafy's Original, Flagship Property Wooshi World
- Education 2.0 Conference To Address The Growing Need For Freelance Career Readiness
- Momcozy Co-Hosts a Cozy Baby Shower at Babylist Beverly Hills
- New Case Study: 37 Years of Improving Emergency Communications at Rush Copley Medical Center
- A Global Celebration of the Industry's Best Voice Over Actors - The Society of Voice Arts and Sciences Announces 2024 Nominees